Feasibility of targeted next-generation sequencing of the TP53 and ATM genes in chronic lymphocytic leukemia

Mansouri, L; Sutton, L-A; Ljungström, V; Sörqvist, E F; Gunnarsson, R; Smedby, K E; Juliusson, G; Stamatopoulos, K; Nilsson, M; Rosenquist, R
March 2014
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p694
Academic Journal
The article presents a study which examines the presence of mutations in ATM and TP53 genes in chronic lymphocytic leukemia (CLL) using HaloPlex-targeted enrichment. A total of 124 CLL samples were studied according to the altered criteria shown by the International Workshop on CLL and demonstrated >70% tumor cells and typical immunophenotype. It reveals that 100% of the TP53 mutations and 13/14 of the ATM mutations were projected to be damaging using PolyPhen bioinformatics.


Related Articles

  • Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL. Halina, Antosz; Artur, Paterski; Barbara, Marzec-Kotarska; Joanna, Sajewicz; Anna, Dmoszyńska // Folia Histochemica et Cytobiologica;2010, Vol. 48 Issue 4, p534 

    B-cell chronic lymphocytic leukaemia (B-CLL) originates from B lymphocytes that may differ in the activation level, maturation state or cellular subgroups in peripheral blood. Tumour progression in CLL B cells seems to result in gradual accumulation of the clone of resting B lymphocytes in the...

  • 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Robak, T; Błoński, J Z; Urbańska-Ryś, H; Błasińska-Morawiec, M; Skotnicki, A B; Błoński, J Z; Urbańska-Ryś, H; Błasińska-Morawiec, M // Leukemia (08876924);Apr99, Vol. 13 Issue 4, p518 

    The aim of the study was to determine the effectiveness of 2-chlorodeoxyadenosine (2-CdA) administered in 2-h i.v. infusions in the treatment of B cell chronic lymphocytic leukemia (B-CLL) in patients 55 years old and younger. One hundred and thirteen patients received three to 10 courses of...

  • Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease. Hertlein, Erin; Beckwith, Kyle A.; Lozanski, Gerard; Chen, Timothy L.; Towns, William H.; Johnson, Amy J.; Lehman, Amy; Ruppert, Amy S.; Bolon, Brad; Andritsos, Leslie; Lozanski, Arletta; Rassenti, Laura; Zhao, Weiqiang; Jarvinen, Tiina M.; Senter, Leigha; Croce, Carlo M.; Symer, David E.; de la Chapelle, Albert; Heerema, Nyla A.; Byrd, John C. // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatments. Here we describe a novel CLL cell line...

  • Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. Lu Qian Wang; Yok Lam Kwong; Kit Fai Wong; Chi Shan Bonnie Kho; Dong Yan Jin; Eric Tse; Rosèn, Anders; Chor Sang Chim // Journal of Translational Medicine;2014, Vol. 12 Issue 1, p1 

    Background TP53 mutation/deletion is uncommon in chronic lymphocytic leukemia (CLL). We postulated that components of TP53-centered tumor suppressor network, miR-34b/c, in addition to DAPK1 and miR-34a might be inactivated by DNA hypermethylation. Moreover, we tested if miR-34b/c methylation...

  • Clinico-pathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: Experience from India. Amare, P. S. Kadam; Gadage, V.; Jain, H.; Nikalje, S.; Manju, S.; Mittal, N.; Gujral, S.; Nair, R. // Indian Journal of Cancer;Jul-Sep2013, Vol. 50 Issue 3, p261 

    BACKGROUND: The present study of 238 B-cell Chronic Lymphocytic Leukemia (B-CLL) patients were undertaken to seek the prevalence and to evaluate clinico-pathological significance of recurrent genetic abnormalities such as del(13q14.3), trisomy 12, del(11q22.3) (ATM), TP53 deletion, del(6q21) and...

  • Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Thornton, Patrick D.; Gruszka-Westwood, Alicja M.; Hamoudi, Rifat A.; Atkinson, Shayne; Kaczmarek, Pawel; Morilla, Ricardo M.; Hilditch, Benjamin L.; A'Hern, Roger; Matutes, Estella; Catovsky, Daniel // Hematology Journal;2004, Vol. 5 Issue 1, p47 

    Abnormalities of TP53 in chronic lymphocytic leukaemia (CLL) correlate with aggressive disease and transformation. We studied 115 patients with CLL including 90 untreated, 25 with heavily pretreated/refractory CLL using fluorescent in situ hybridisation (FISH) to detect allelic loss at...

  • CLL: Biology.  // Hematology Journal;2004 Supplement 2, Vol. 5, pS137 

    Presents abstracts of studies on chronic lymphocytic leukemia, focusing on biological aspects. Recognition of MIC-A and ULBP3 by VD1 T cells in B-CLL: Implications for anti-cancer surveillance; PRAME antigen is frequently expressed in lymphoproliferative diseases; P53 expression in chronic...

  • ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Pospisilova, S; Gonzalez, D; Malcikova, J; Trbusek, M; Rossi, D; Kater, A P; Cymbalista, F; Eichhorst, B; Hallek, M; Döhner, H; Hillmen, P; van Oers, M; Gribben, J; Ghia, P; Montserrat, E; Stilgenbauer, S; Zenz, T // Leukemia (08876924);Jul2012, Vol. 26 Issue 7, p1458 

    Recent evidence suggests that - in addition to 17p deletion - TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data from retrospective analyses and prospective clinical trials show that ∼5% of untreated CLL patients with treatment indication have a...

  • Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Lin, K; Rockliffe, N; Johnson, G G; Sherrington, P D; Pettitt, A R // Oncogene;4/10/2008, Vol. 27 Issue 17, p2445 

    In chronic lymphocytic leukaemia (CLL), mutation/deletion of TP53 is strongly associated with early disease progression, resistance to chemotherapy and short patient survival. Consequently, there is a pressing need to develop novel treatment protocols for this high-risk patient group. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics